A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated due to inability to recruit the target number of patients. There were no safety and/or efficacy concerns involved in the decision to stop enrollment.

Conditions

Melanoma

Interventions

DRUG: encorafenib
DRUG: binimetinib
DRUG: pembrolizumab
DRUG: ipilimumab
DRUG: nivolumab

Sponsor

Pfizer

Collaborators

[object Object]